Murrayanine Induces Cell Cycle Arrest, Oxidative Stress, and Inhibition of Phosphorylated p38 Expression in A549 Lung Adenocarcinoma Cells

The anticancer activity of carbazole alkaloids

Chemotherapy is the first choice for the majority of cancers, but severe side effects and drug resistance restrict the actual clinical efficacy. Carbazole alkaloids, mainly from the Rutaceae family, possess favorable donor ability, good planarity, rich photophysical properties, and excellent biocompatibility. Carbazole alkaloids could not only intercalate in DNA but could also inhibit telomerase and topoisomerase and regulate protein phosphorylation. Hence, carbazole alkaloids are useful in providing lead hits/candidates for the development of novel anticancer agents. This review summarizes the research progress made regarding the anticancer properties of carbazole alkaloids, covering articles published from January 2010 to June 2021.

Retracted: Murrayanine Induces Cell Cycle Arrest, Oxidative Stress, and Inhibition of Phosphorylated p38 Expression in A549 Lung Adenocarcinoma Cells

An editorial decision has been made to retract this manuscript due to breach of publishing guidelines, following the identification of non-original and manipulated figures. Reference: Jingbao Zhang, Yanfei Gao, Changbo Ma, Yi Wang: Murrayanine Induces Cell Cycle Arrest, Oxidative Stress, and Inhibition of Phosphorylated p38 Expression in A549 Lung Adenocarcinoma Cells. Med Sci Monit 2019; 25:2002-2008. 10.12659/MSM.913873.

A Review of the Anti-Cancer Potential of Murraya koenigii (Curry Tree) and Its Active Constituents

Murraya koenigii (MK) relates to the Rutaceae family and has many health benefits. To date, over eighty-eight carbazole alkaloids along with terpenoids, and other nutrients have been identified from different parts of this plant. This review presents accumulated information regarding the role of MK and its constituents in the prevention/treatment of cancer. Literature survey revealed that MK and its constituents target multiple deranged pathways associated with apoptosis, growth (JAK-STAT, mTOR), and cell cycle in a variety of cancerous cell lines (colon, lung, liver, skin, prostate, breast, etc.) and few animal models. Thus, the present review highlights the anticancer mechanism of MK and its phytoconstituents, and further future perspectives. The ameliorating effects of MK and its phytoconstituents against various cancers warrant its multi-institutional clinical trials as soon as possible. The prospects of relatively cheaper cancer drugs could then be brighter, particularly for the socio-economically feebler cancer patients of the world.

Butyrate Inhibits Deoxycholic-Acid-Resistant Colonic Cell Proliferation via Cell Cycle Arrest and Apoptosis: A Potential Pathway Linking Dietary Fiber to Cancer Prevention

SCOPE

Butyrate, an intestinal microbiota metabolite of dietary fiber, exhibits colon cancer preventive effects. In contrast, a high fat intake increases fecal secondary bile acids, such as deoxycholic acid (DCA, a potential cancer promoter), which selectively enrich mutant epithelial cells with an abnormally high resistance to DCA-induced apoptosis in the colon. This study is conducted to test the hypothesis that physiological concentrations of butyrate inhibit DCA-resistant colonic cell proliferation.

METHODS AND RESULTS

With human HCT-116 cells as parental colonic cells, a human DCA-resistant colonic cell line (DCA-RCL) is developed. DCA treatment increases apoptosis and intracellular reactive oxygen species (an apoptotic trigger) at a rate threefold greater in HCT-116 cells than in DCA-RCL cells. Subsequently, 41 apoptosis related genes (including signaling pathways) with greater than onefold (mRNA) change in DCA-RCL cells are identified compared with HCT-116 cells. Moreover, butyrate treatment inhibits DCA-RCL cell proliferation with similar efficacy when compared with HCT116 cells via cellular myelocytomatosis oncogene (c-Myc)/p38 mitogen-activated protein kinase pathway.

CONCLUSION

It is demonstrated that butyrate inhibits DCA-RCL cell proliferation at the cellular and molecular level. These data provide a proof of concept that butyrate can protect against colon carcinogenesis through a specific targeting of DCA-resistant colonic cells.